Market Report, "Analgesics in Denmark", published

In order to limit the consumption of analgesics among consumers in Denmark and to further reduce the number of deaths and other health problems related to the consumption of such medicines, the Danish Health and Medicines Authority ordered that, from 30 September 2013, all analgesics in large pack sizes would be switched from OTC to Rx status, with all such purchases requiring a prescription from a doctor. Smaller pack sizes are still available OTC, however, in various distribution channels. The result of this in 2015 was 2% volume growth in analgesics, a rate of growth which was weaker than the current value growth recorded in the category during 2014 as more consumers obtained prescriptions from their doctors to buy analgesics. The 3% current value growth recorded in the category 2015 was also slower than the 7% current value growth recorded in the category 2014. The unit prices charged for analgesics in small packs are higher than the prices charged for the same products in larger packs and, as a result, current value growth remained positive overall in the category in 2015. Consumers are generally familiar with these changes to the regulations, although many of them still prefer the option of quickly purchasing small packs of analgesics and paying relatively higher prices rather than visiting a doctor’s clinic just for the purpose of obtaining a prescription for an OTC analgesic.

Full Report Details at
- http://www.fastmr.com/prod/1082060_analgesics_denmark.aspx?afid=301

Competitive Landscape

Takeda Pharma A/S led analgesics in Denmark throughout the review period as well as in 2015, with the company holding a 41% value share the end of the review period. The company is strong in analgesics due to its leading brands Pamol and Ipren. These brands continue to benefit from being common recommendations by staff working in chemists/pharmacies, while the company also undertakes various marketing campaigns to ensure consistently high consumer recognition of these brands and consistent availability of the product in various formats. Ipren for example, is available in gel format, packaged in squeezable 50g tubes in addition to the standard format of tablets.

Industry Prospects

Over the forecast period, analgesics is expected to decline in value at a CAGR 1% in 2015 constant prices to reach DKK612 million by the end of 2020. This negative performance is expected to come as no surprise following recent changes in regulation stating that, from September 2013, all analgesics in large packaging sizes must be sold as Rx medicines under prescription. It is most likely that many Danish consumers will opt to see a doctor and obtain a prescription before buying analgesics as this will enable them to save money over the second option of buying OTC analgesics in smaller packaging sizes at higher unit prices.

Report Overview

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Analgesics in South Korea
- Analgesics in Tunisia
- Analgesics in the United Arab Emirates
- Analgesics in Mexico
- Analgesics in Algeria